FoundationOne maximises the detection of biomarkers associated with potentially effective therapies
FoundationOne can help you to maximise therapy options by detecting genomic alterations present in 315 genes and 28 select introns that are known to be associated with cancer, across 4 types of alteration class.1 FoundationOne can additionally detect microsatellite instability (MSI) and tumour mutational burden (TMB) biomarkers that are increasingly associated with the effectiveness of immunotherapies.2,3
FoundationOne can detect 4 classes of genomic alterations plus biomarkers associated with response to immunotherapy2–4
What genes are tested using FoundationOne?
FoundationOne is a leader in clinical genomic profiling, detecting more alterations than other testing methods5–8
Compared with many other techniques such as fluorescence in situ hybridisation (FISH) and immunohistochemistry (IHC), FoundationOne offers improved detection levels because it uses hybrid capture-based next-generation sequencing (NGS) to sequence the entire coding regions of hundreds of known cancer-related genes, providing high uniform coverage across all genes sequenced, ensuring that common and rare alterations are identified, with high sensitivity.5–8 This technique allows for the identification of common and rare mutations.4 The service provides a rapid turnaround, giving clinicians the chance to act quickly on the findings. FoundationOne genomic profiling is also supported by one of the world’s most comprehensive patient genomic databases and backed by global experts in the field, ensuring a high quality, comprehensive report, and access to these experts should any assistance be required following receipt of the report.
FoundationOne provides comprehensive genomic profiling, so it is not necessary to pre-specify an alteration of interest. It is shown that the majority of potentially clinically relevant alterations can be missed using traditional profiling approaches that test for predefined alterations based upon physician expectations.6–11 In a study of approximately 7,300 solid tumour specimens, the potential benefit of targeted therapy for known oncogenic ERBB2 (also known as HER2) alterations, common to breast, gastric and gastroesophageal (GE) cancers, was investigated. In this study, ERBB2 alterations were detected in 27 different tissue types, and ERBB2 amplification alterations that were detected in GE junction, breast and gastric cancers accounted for only 30% of all known oncogenic ERBB2 alterations detected.7
Performing comprehensive hybrid capture-based NGS led to the detection of base substitution, rearrangement, insertion/deletion and amplification genomic alterations across the entire range of cancer types tested. The findings of this study highlight that, compared with current clinical standards, comprehensive genomic profiling could more accurately identifty patients that could benefit from ERBB2-targeted therapies.*7
The superior level of detection that FoundationOne offers over NGS hotspot analysis is proven in several studies:
- FoundationOne technical information.
- Chalmers ZR et al. Genome Med 2017; 9:34.
- Castro MP et al. J. Immunother 2015; 3:58.
- Frampton, GM et al. Nat Biotechnol 2013; 31:1023–1031
- Schrock AB et al. Clin Cancer Res 2016; 13:3281–3285.
- Ali SM et al. Oncologist 2016; 6:762–670.
- Chmielecki J et al. Oncologist 2015; 20:7–12.
- Rozenblum AB et al. J Thorac Oncol 2017; 2:258–268 (and supplementary material).
- Chen AY-Y and Chen A. J Invest Dermatol 2013; 133:e8.
- Bridge JA. J Orthop Sci 2008; 13:273–282.
- Angulo B et al. PLoS One 2012; 8:e43842.
- Bishop R. Bioscience Horizons 2010; 1:85–95.
- Hu L et al. Biomark Res 2014; 2:3.
- Lin F and Prichard J (eds). Handbook of Practical Immunohistochemistry 2015. Frequently Asked Questions, 2nd edition. Springer Science+Business Media 2015.
- Pekar-Zlotin M et al. The Oncologist 2015; 20:316–322.
- Leong T Y-M et al. Adv Anat Pathol 2010; 17:404–418.
- Suh JH et al. The Oncologist 2016; 21:684–691.
- Drilon A et al. Clin Cancer Res 2015; 21:3631–3639.
- Rankin A et al. The Oncologist 2016; 11:1306–1314.